390387-79-8

Basic information

• Product Name: 3-(3,5-difluoro-phenyl)-2-oxo-propionic acid
• CAS NO: 390387-79-8
• Molecular Weight: 200.142
• Mol File: 390387-79-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-(3,5-difluoro-phenyl)-2-oxo-propionic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3,5-difluoro-phenyl)-2-oxo-propionic acid(390387-79-8)
• EPA Substance Registry System: 3-(3,5-difluoro-phenyl)-2-oxo-propionic acid(390387-79-8)

Safety Data

• Hazardous Substances Data: 390387-79-8(Hazardous Substances Data)

Upstream product

• 31105-91-6 (S)-2-amino-3-(3,5-difluorophenyl)propanoic acid 
• 266360-63-8 3,5-difluoro-D-phenylalanine 
• 84315-23-1 3,5-difluorocinnamic acid 
• 266360-46-7 2-acetylamino-2-(3,5-difluoro-benzyl)-malonic acid diethyl ester 
• 141776-91-2 1-bromomethyl-3,5-difluoro-benzene 
• 32085-88-4 3,5-difluorobenzaldehyde 
• 390387-78-7 4-(3,5-difluoro-benzyl)-2-trifluoromethyl-oxazol-5-ol 
• 32133-37-2 rac-3,5-difluorophenylalanine 

Relevant articles and documents

Synthesis of D- and L-Phenylalanine Derivatives by Phenylalanine Ammonia Lyases: A Multienzymatic Cascade Process

The synthesis of substituted D-phenylalanines in high yield and excellent optical purity, starting from inexpensive cinnamic acids, has been achieved with a novel one-pot approach by coupling phenylalanine ammonia lyase (PAL) amination with a chemoenzymatic deracemization (based on stereoselective oxidation and nonselective reduction). A simple high-throughput solid-phase screening method has also been developed to identify PALs with higher rates of formation of non-natural D-phenylalanines. The best variants were exploited in the chemoenzymatic cascade, thus increasing the yield and ee value of the D-configured product. Furthermore, the system was extended to the preparation of those L-phenylalanines which are obtained with a low ee value using PAL amination.

Optimization and mechanistic studies of psammaplin A type antibacterial agents active against methicillin-resistant Staphylococcus aureus (MRSA)

As described in the preceding article, utilizing a novel combinatorial disulfide exchange strategy, a library of psammaplin A (1) analogues was constructed and screened for antibacterial activity leading to the identification of a collection of diverse lead compounds. These combinatorial leads were subsequently refined, through parallel synthesis, to afford a series of highly potent antibacterial agents (e.g. 17, 57, 58, 69, and 70), some possessing greater than 50-fold higher activities than the natural product. Evaluation of the selectivity and serum binding properties of some of the most promising compounds and preliminary studies directed at deciphering the mechanism of action of this novel class of antibacterial agents are also included.